These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 1791768)

  • 81. Oestradiol and testosterone implants.
    Studd JW; Smith RN
    Baillieres Clin Endocrinol Metab; 1993 Jan; 7(1):203-23. PubMed ID: 8435053
    [No Abstract]   [Full Text] [Related]  

  • 82. Oestradiol implants for gender-affirming hormone therapy: an observational study of serum oestradiol levels and consumer survey.
    Mesure J; Afrin S; Fitzgerald S; Luu J; Gibberd A; Leigh L; Wynne K
    Sex Health; 2023 Dec; 20(6):550-557. PubMed ID: 37845025
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Dydrogesterone treatment for menstrual-cycle regularization in abnormal uterine bleeding - ovulation dysfunction patients.
    Wang L; Guan HY; Xia HX; Chen XY; Zhang W
    World J Clin Cases; 2020 Aug; 8(15):3259-3266. PubMed ID: 32874980
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Too much of a good thing? Two cases of oestrogen overdosage associated with oestradiol implants.
    Eden J
    Med J Aust; 1990 May; 152(10):558. PubMed ID: 2338934
    [No Abstract]   [Full Text] [Related]  

  • 85. A first study to compare two dosages of dydrogesterone in opposing the 50 mg oestradiol implant.
    Rees M; Leather A; Pryse-Davies J; Collins SA; Barlow DH; Studd JW
    Maturitas; 1991 Dec; 14(1):9-15. PubMed ID: 1791775
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Endometrial histology and bleeding patterns in post-menopausal women taking sequential, combined estradiol and dydrogesterone.
    Ferenczy A; Gelfand MM
    Maturitas; 1997 Apr; 26(3):219-26. PubMed ID: 9147354
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Endometrial safety of continuous combined hormone replacement therapy with 17beta-oestradiol (1 or 2 mg) and dydrogesterone.
    Bergeron C; Ferenczy A
    Maturitas; 2001 Jan; 37(3):191-9. PubMed ID: 11173181
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Continuous combined hormone replacement therapy with 1 mg 17beta-oestradiol and 5 mg dydrogesterone (Femoston-conti): endometrial safety and bleeding profile.
    Quereux C; Pornel B; Bergeron C; Ferenczy A
    Maturitas; 2006 Feb; 53(3):299-305. PubMed ID: 16043317
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Dydrogesterone to oppose the 100 mg oestradiol implant.
    Greenwood PA; Jesinger DK
    Maturitas; 1991 Dec; 14(1):17-21. PubMed ID: 1791768
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Estradiol and dydrogesterone. A review of their combined use as hormone replacement therapy in postmenopausal women.
    Foster RH; Balfour JA
    Drugs Aging; 1997 Oct; 11(4):309-32. PubMed ID: 9342560
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Progestational effects of dydrogesterone in vitro, in vivo and on the human endometrium.
    Schindler AE
    Maturitas; 2009 Dec; 65 Suppl 1():S3-11. PubMed ID: 19969432
    [TBL] [Abstract][Full Text] [Related]  

  • 92.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 93.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 94.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 95.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 96.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 97.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 98.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 99.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 5.